Indeed, our recent data from the Action in Diabetes and Vascular Disease: PreterAx and Diamicron MR Controlled Evaluation (ADVANCE) trial of patients with long-standing type 2 diabetes mellitus (a high-risk group) suggested that both NT-proBNP and hsTnT were much stronger predictors than was seen in the studies reported here.10 Recent data from Multi-Ethnic Study of Atherosclerosis (MESA) suggests that ethnicity is unlikely to importantly modify the predictive ability of cardiac biomarkers.23 Therefore, generalizability of cardiac biomarkers in CVD prediction is an ongoing area of interest. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.